2026-04-14T02:17:51Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1338372025-12-05T04:21:37Zcom_2072_1057col_2072_478809col_2072_478917
Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin
Sicras Mainar, Antoni
Rejas, Javier
Pérez-Paramo, Maria
Sánchez-Álvarez, Luis
Navarro-Artieda, Ruth
Darbà, Josep
Medicaments
Medicaments genèrics
Anàlisi cost-benefici
Neuropsicofarmacologia
Tractament del dolor
Ansietat
Drugs
Generic drugs
Cost effectiveness
Neuropsychopharmacology
Pain treatment
Anxiety
Background: Discrepancies are seen between arguments in favor of and against prescribing generic versus brand-name drugs. Objective: To provide real-world evidence on treatment persistence, economic and clinical outcomes of pregabalin, generic versus brand-name (Lyrica®, Pfizer), routinely used to treat neuropathic pain (NP) or generalized anxiety disorder (GAD). Methods: Electronic medical records from subjects' first starting treatment with pregabalin between January-2015 and June-2016 were analyzed. Persistence, resources utilization, and costs were assessed, along with remitter and responder rates. (...)
2019-05-24T07:41:51Z
2020-02-28T06:10:17Z
2019-02
2019-05-24T07:41:51Z
info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
Versió postprint del document publicat a: https://doi.org/10.1080/14737167.2019.1519399
Expert Review of Pharmacoeconomics & Outcomes Research, 2019, vol. 19, num. 1, p. 45-57
https://doi.org/10.1080/14737167.2019.1519399
(c) Informa Healthcare, 2019
info:eu-repo/semantics/openAccess
Informa Healthcare
Articles publicats en revistes (Economia)